Oza AM, Estevez-Diz MDP, Grischke EM, Hall M, et al. A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin Cancer Res 2020 Jul 1. pii: 1078-0432.CCR-20-0219.
PMID: 32611648